$ACT Recent Headlines DEA restricts narcotic pain-drug

New Post Public Reply Private Reply Replies (0) Message Board

Sep 9, 2014 at 11:33 AM

$ACT Recent Headlines

DEA restricts narcotic pain-drug prescriptions 7:27 p.m. Aug. 21, 2014 - Louise Radnofsky
Actavis raises guidance as earnings top views 8:11 a.m. Aug. 5, 2014 - MarketWatch.com
Nasdaq needs to turn up the volume 11:59 a.m. July 17, 2014 - The Trading Deck
Leon Cooperman talks up Citi, Thermo Fisher 11:20 a.m. July 16, 2014 - Sue Chang
Leon Cooperman likes Thermo Fisher, Citi, Actavis 11:06 a.m. July 16, 2014 - Sue Chang
10 biggest S&P 500 winners and losers for 2014 10:44 a.m. July 1, 2014 - Philip van Doorn
Affiliated Managers Group to join S&P 500 5:33 p.m. June 24, 2014 - Wallace Witkowski
10 best-performing S&P 500 stocks of 2014 2:38 p.m. June 2, 2014 - Philip van Doorn
Pfizer's plan to relocate after merger deal draws lawmakers' fire 11:30 a.m. May 9, 2014 - Russ Britt
Corner drug store may move overseas to save on taxes 6:31 a.m. April 16, 2014 - Al Lewis
Intuitive Surgical slumps; Facebook extends rally 3:41 p.m. April 9, 2014 - Sue Chang
Actavis acquires Silom Medical for $100 million 10:19 a.m. April 1, 2014 - MarketWatch.com
The 10 most overbought stocks in the S&P 500 index 12:19 p.m. March 25, 2014 - The Trading Deck
UK drug rejection, patent concerns take a bite out of Celgene shares 1:33 p.m. March 14, 2014 - Russ Britt
Mylan to start selling generic Celebrex in May 7:23 a.m. March 13, 2014 - MarketWatch.com
Pfizer loses Celebrex patent ruling; shares halted but effect muted 3:21 p.m. March 12, 2014 - Russ Britt
Staples awash in red; eBay up as Icahn posts new letter 5:09 p.m. March 6, 2014 - Sue Chang
Icahn Enterprises reports profit up 144% in 2013 11:23 a.m. March 3, 2014 - MarketWatch
Citadel hedge fund’s recent moves 12:12 p.m. Feb. 25, 2014 - Insider Monkey
Stocks rally; S&P 500 ends right below record 5:46 p.m. Feb. 24, 2014 - Victor Reklaitis

Actavis' Antibiotic under FDA Review, Response in 1Q15 - Analyst Blog 5:20 p.m. Sept. 8, 2014 - Zacks.com
Synergy Pharmaceuticals Could Be A Diamond In The Rough 12:30 p.m. Sept. 8, 2014 - Seeking Alpha
Pfizer: You Won't Fool Me Twice 1:28 a.m. Sept. 7, 2014 - Seeking Alpha
IBD 50 Showing Little Distress, But Few Big Winners 5:45 p.m. Sept. 5, 2014 - Investors Business Daily
Orexigen Gets Weight Loss Drug Patent, May See Runup Into Approval Decision 11:46 a.m. Sept. 5, 2014 - Seeking Alpha
The Top Net Buys Of The Hedge Fund Gurus 5:59 p.m. Sept. 4, 2014 - GuruFocus.com
Actavis' Gastrointestinal Drug Under FDA Priority Review - Analyst Blog 4:30 p.m. Sept. 4, 2014 - Zacks.com
3 Stocks Advancing The Health Care Sector 1:03 p.m. Sept. 4, 2014 - TheStreet.com
Sterne Agee Raises Actavis plc Estimates, Price Target 10:58 a.m. Sept. 4, 2014 - benzinga.com
Shares Of Actavis Are Up ~1.5% On FDA Approval 9:55 a.m. Sept. 4, 2014 - benzinga.com
UPDATE: Morgan Stanley Reiterates On Actavis plc As M&A Could Offer Additional Upside 9:00 a.m. Sept. 4, 2014 - benzinga.com
Actavis's Watson Labs ANDA Approved By FDA 8:41 a.m. Sept. 4, 2014 - benzinga.com
New Lifetime High For Actavis (ACT) 9:46 a.m. Sept. 3, 2014 - TheStreet.com
FDA accepts eluxadoline NDA 2:02 p.m. Sept. 2, 2014 - Seeking Alpha
UCB Files Patent Infringement Lawsuit vs. Actavis - Analyst Blog 4:40 p.m. Aug. 28, 2014 - Zacks.com
Top 4 BlackRock Funds to Buy Now 6:34 a.m. Aug. 28, 2014 - InvestorPlace.com
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2014 Update 10:34 a.m. Aug. 23, 2014 - Seeking Alpha
Supernus' Trokendi XR Faces Generic Threat from Actavis - Analyst Blog 4:55 p.m. Aug. 22, 2014 - Zacks.com
Clampdown on Popular Painkillers 12:18 p.m. Aug. 22, 2014 - The Wall Street Journal Interactive Edition
Wall Street Breakfast: Restrictions Imposed On Citigroup's Hedge Fund Sales 6:33 a.m. Aug. 22, 2014 - Seeking Alpha

Equity Coverage on Pharma Industry - Zoetis, Actavis, Horizon Pharma, Hospira, and Endocyte 8:55 a.m. Today - PR Newswire - PRF
Actavis Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, a Qualified Infectious Disease Product 8:00 a.m. Sept. 5, 2014 - PR Newswire - PRF
Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 9:20 a.m. Sept. 2, 2014 - PR Newswire - PRF
Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth 9:10 a.m. Aug. 29, 2014 - PR Newswire - PRF
Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 4:05 p.m. Aug. 26, 2014 - PR Newswire - PRF
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers 8:50 a.m. Aug. 21, 2014 - PR Newswire - PRF
Depomed Prevails in Gralise® ANDA Litigation Blocking Generic Entry Until 2024 11:15 a.m. Aug. 19, 2014 - PR Newswire - PRF
Actavis Announces Positive Topline Results From The Phase III Program Of Ceftazidime-Avibactam In Patients With Complicated Intra-Abdominal Infections(cIAI) 7:24 a.m. Aug. 19, 2014 - PR Newswire - PRF
Collaborations, Financial Results, and Technical Updates - Research Reports on Actavis, UnitedHealth, Bristol-Myers Squibb, Celgene and Aetna 8:40 a.m. Aug. 12, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42 7:00 a.m. Aug. 5, 2014 - PR Newswire - PRF
Earnings Releases, Technical Updates, FDA Acceptances, and New Products - Research Reports on Newfield Exploration, YPF, HCA, Actavis and 3M 8:50 a.m. Aug. 4, 2014 - PR Newswire - PRF
Medicines360 and Actavis Announce FDA Acceptance for Filing of NDA for Levosert™ IUD 4:30 p.m. July 21, 2014 - PR Newswire - PRF
Drug Application Submission, Merger Agreement, Launch of Newly Approved Drug, and Acquisition - Analyst Notes on Actavis, Salix, Mylan, Zoetis and Hospira 5:10 a.m. July 14, 2014 - PR Newswire - PRF
Actavis Confirms Generic Diclegis® Patent Challenge 4:25 p.m. July 11, 2014 - PR Newswire - PRF
Actavis Confirms Generic Ampyra® Patent Challenge 4:05 p.m. July 8, 2014 - PR Newswire - PRF
Board Changes, Patents, Recognitions, and Technical Updates - Analyst Notes on Actavis, Celldex Therapeutics, Galena Biopharma, PTC Therapeutics and Theravance Biopharma 5:30 a.m. July 4, 2014 - PR Newswire - PRF
Impax Acquires Two Products from Actavis 4:05 p.m. July 2, 2014 - PR Newswire - PRF
Actavis Completes Acquisition of Furiex Pharmaceuticals 8:46 a.m. July 2, 2014 - PR Newswire - PRF
Actavis Announces Final Stockholder Merger Consideration Election Results in Connection with Forest Laboratories Acquisition 8:00 a.m. July 2, 2014 - PR Newswire - PRF
Furiex Stockholders Approve Acquisition by Actavis; Ukrainian Antimonopoly Committee Clears Proposed Merger 3:15 p.m. July 1, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SMPL Faces Legal Drama: What Investors Need to Know

Investors Swim Against the Current With SMPL Picture this: You’re sipping your morning coffee, glancing through stocks, only to choke on your bagel when The Simply Good Foods Company (NASDAQ: SMPL) pops up with some less-than-palatable news. A class action is brewing, shouting out to investors who took the bait from October 24, 2024, to April 8, 2026. If you’re one of...

U.S. Green Beret's Mission: Clearing Landmines in Ukraine

The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...

OneOdio Showcases Innovation at IFA 2026 in Berlin

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

D-Wave Faces Legal Questions After CFO Exit and Losses

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Pizza: The Unlikely Symbol of Universal Togetherness

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Damp or Dry: The Battle for Healthy Air in Colorado

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...